Drugs / ATI-501
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03594227 Comparator | Jun 2018 → Jun 2019 | alopecia | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-07-30 | Aclaris Therapeutics, Inc. | Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint aclaristx.com ↗ |
| 2018-06-26 | Aclaris Therapeutics, Inc. | Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis aclaristx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATI-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03594227 ↗ |
| Route | Oral | “ATI-501 400mg BID oral low dose for oral administration” NCT03594227 ↗ |